Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848504 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2848501 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13436045 | 0.87 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13461935 | 0.85 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL765252 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2303457 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL10476597 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16840443 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL636682 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL637101 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | CHRNB2 3610/4885CHRNA4 4286/4885CHRNB4 3732/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | CHRNB2 3765/4885CHRNA4 4480/4885CHRNB4 4109/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | CHRNB2 3311/4885CHRNA4 4190/4885CHRNB4 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.